购物车
全部删除
您的购物车当前为空
别名 PF-06439015, PF06439015, PF 06439015
PF-06439015 overcomes clinical ALK (receptor tyrosine kinase anatropic lymphoma kinase) mutations resistant to krizotinib. Pf-06439015 is an effective selective inhibitor.

PF-06439015 overcomes clinical ALK (receptor tyrosine kinase anatropic lymphoma kinase) mutations resistant to krizotinib. Pf-06439015 is an effective selective inhibitor.
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25 mg | 待询 | 3-6月 | |
| 50 mg | 待询 | 3-6月 | |
| 100 mg | 待询 | 3-6月 |
| 产品描述 | PF-06439015 overcomes clinical ALK (receptor tyrosine kinase anatropic lymphoma kinase) mutations resistant to krizotinib. Pf-06439015 is an effective selective inhibitor. |
| 别名 | PF-06439015, PF06439015, PF 06439015 |
| 分子量 | 470.52 |
| 分子式 | C22H23FN6O3S |
| CAS No. | 1549629-82-4 |
| Smiles | [C@@H](OC=1C=C(C=NC1N)C=2SC([C@](CO)(C)O)=NC2C)(C)C3=C(C=CC(F)=C3)N4N=CC=N4 |
| 密度 | 1.47 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
对于不同动物的给药剂量换算,您也可以参考 更多